RITM Q1 2026 Earnings Modest EPS Beat Highlights Steady Portfolio Performance Cardiol Therapeutics CRDL Q4 2025 Earnings Narrower Loss Surpasses Estimates as PreRevenue Biotech Advances Pipeline ARTNA Q3 2025 Earnings Slight EPS Beat Amid Steady Utility Performance ACRS Q1 2026 Earnings Narrower Loss Beats Estimates as Pipeline Progress Continues SLNO Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Reports a Surprising Profit National Research Corporation NRC Q1 2026 Earnings EPS of 021 Reported Amid Limited Market Expectations